Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes by Tushuizen, M.E. et al.
REVIEW
Postprandial dysmetabolism and cardiovascular disease in
type 2 diabetes
M E Tushuizen, M Diamant, R J Heine
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Postgrad Med J 2005;81:1–6. doi: 10.1136/pgmj.2004.020511
The worldwide prevalence of type 2 diabetes mellitus has
reached epidemic proportions. The so-called traditional
risk factors cannot fully explain the excessive
cardiovascular disease risk of type 2 diabetic patients.
Numerous studies indicate that postprandial metabolic
derangements, most notably hyperglycaemia and
hypertriglyceridaemia, which are exaggerated and
prolonged in type 2 diabetes, are important cardiovascular
disease risk factors since they induce oxidative stress and
endothelial dysfunctions. This review discusses the current
evidence showing that postprandial dysmetabolism may
indeed constitute an important cardiovascular disease risk
factor as well as the mechanisms underlying this
association. Finally, some possible therapeutic options and
recommendations for future research are discussed.
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T
he worldwide prevalence of type 2 diabetes
mellitus is growing rapidly, reaching epi-
demic proportions.1 One of the major reasons
of the increased prevalence in developing coun-
tries is the adoption of the so-called western
lifestyle—that is, a high intake of energy dense
food and a low physical activity pattern. These
lifestyle changes lead to one of the key abnorm-
alities underlying type 2 diabetes mellitus—that
is, insulin resistance. Insulin resistance is asso-
ciated with central obesity, hyperinsulinaemia,
polycystic ovary syndrome, hypertension, and
dyslipidaemia.2 3 Hyperglycaemia, the estab-
lished diagnostic marker of diabetes mellitus, is
the result of the second key feature, progressive
pancreatic b-cell failure.
It is well recognised that type 2 diabetic
patients have an excess risk of developing
atherosclerosis, resulting in high cardiovascular
disease morbidity and mortality.4 Therefore, with
the rise of the prevalence of diabetes, it may be
expected that the global burden of cardiovascular
disease will also increase. Since the so-called
traditional risk factors such as high cholesterol,
hypertension, smoking, and low high density
lipoprotein (HDL) cholesterol, cannot fully
explain the excessive cardiovascular disease risk
of type 2 diabetic patients, other risk factors need
to be identified.5
Two important processes involved in the
development of atherosclerosis, the underlying
cause of cardiovascular disease, are inflamma-
tion and coagulation activation.6 Although the
exact mechanisms underlying atherogenesis are
still not completely understood, vascular endo-
thelial dysfunction is generally believed to be
the starting point.6 7 Under normal conditions,
the multiple functional characteristics of the
endothelium, including regulation of the vascu-
lar tone, thrombogenesis, vascular wall perme-
ability, and cell growth, collectively protect the
vascular system.7 Adequate production of nitric
oxide has a pivotal role in the majority of these
processes. Since endothelial functions cannot be
measured directly, several indirect methods have
been developed to estimate these functions.
These include the assessment of plasma concen-
trations of endothelial-cell derived proteins,
including von Willebrand’s factor (vWF), vascu-
lar cell adhesion molecule-1 (VCAM-1) and
intercellular adhesion molecule-1 (ICAM-1),7 as
well as the more complicated measurement of
nitric oxide-dependent vasodilatation or flow-
mediated dilatation (FMD) of the brachial artery
by non-invasive ultrasound.8 Increased plasma
concentrations of vWF, VCAM-1 and ICAM-1,
and a decreased FMD have been associated with
an increased risk of cardiovascular disease.7 8
Other cardiovascular disease risk factors which
have been recognised recently include hyper-
homocysteinaemia, raised plasma levels of
C-reactive protein, reflecting a low grade inflam-
matory state, fibrinogen, representing a hyper-
coagulable state, and oxidised low density
lipoprotein (LDL), as an indicator of oxidative
stress.9 10 However, only recently, the excessive
and prolonged metabolic disturbances occurring
in the postprandial state in type 2 diabetic
subjects have regained interest as potential
cardiovascular disease risk factors.11
Already over 200 years ago, William Heberden
made the first observation regarding a postpran-
dial effect on the circulation of blood,12 and in
the late 1970s of the last century, Zilversmit
postulated that atherosclerosis is a postpran-
dial phenomenon.13 Ever since, a large body of
evidence has accumulated indicating a relation
between postprandial dysmetabolism, especially
hyperglycaemia and hypertriglyceridaemia, and
the risk of cardiovascular disease.11 14–17
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In this review we will briefly discuss the present evidence
for postprandial dysmetabolism as a potential cardiovascular
disease risk factor, with special emphasis on postprandial
glucose and lipid dysmetabolism. To this purpose, the asso-
ciation of postprandial dysmetabolism with the presence of
(indicators of) atherosclerotic vascular disease and the pos-
sible underlying mechanisms will be reviewed.
POSTPRANDIAL HYPERGLYCAEMIA
Various mechanisms keep the plasma glucose levels in
healthy subjects between strict limits, even after a carbohy-
drate load. The insulin response after a meal regulates the
glucose uptake from the blood into the peripheral tissues and
inhibits gluconeogenesis and glycogenolysis in the liver.
Dysfunction of b-cells (for example, loss of the normal
insulin secretion pattern) and insulin resistance contribute to
glucose intolerance and both can be found very early in the
disease process, finally leading to type 2 diabetes.2
In the United Kingdom Prospective Diabetes Study, low-
ering of glycated haemoglobin mainly reduced long term
microvascular complications of diabetes, whereas effects on
macrovascular disease were less convincing.18 In apparent
contrast, several epidemiological studies have shown an
association between two hour glucose concentrations after a
75 g glucose load (2hPG) and the occurrence of cardiovas-
cular disease in the general population.19 20 A meta-analysis of
20 studies with more than 95 000 people demonstrated a
continuous relationship between postload glucose levels and
cardiovascular disease risk extending into the non-diabetic
range.19 The Diabetes Epidemiology: Collaborative analysis Of
Diagnostic criteria in Europe (DECODE) study demonstrated
that the 2hPG concentrations, even in subjects with normal
fasting glucose, were associated with mortality, independent
of fasting plasma glucose concentrations.20
Chronic hyperglycaemia has been associated with impaired
endothelial function.21 Recent studies in healthy and type 2
diabetic subjects indicate that acute hyperglycaemia causes
endothelial dysfunction as measured by FMD.22 Also,
circulating ICAM-1 plasma levels significantly increased in
both diabetic and normal subjects after an oral glucose
tolerance test, suggesting endothelial cell activation.23
Ceriello and co-workers have shown that postprandial
hyperglycaemia is accompanied by several alterations of the
coagulation system.24 25 An oral glucose load in both healthy
and type 2 diabetes patients caused a shortening of the half
life of fibrinogen and an increase in plasma fibrinopeptide A
and the fragments of prothrombin and factor VII. In addition,
acute, short term hyperglycaemia resulted in a transient
hyper-reactivity of platelets to high shear stress, combined
with a significant rise of plasma vWF in patients with type 2
diabetes.26 Taken together, these findings suggest that hyper-
glycaemia may induce a hypercoagulable state.
In healthy subjects and those with impaired glucose tole-
rance, consecutive pulses of intravenous glucose increased
circulating cytokine concentrations (interleukin-6 and
tumour necrosis factor-a) to a greater extent than during
similar blood glucose levels which were kept stable during a
hyperglycaemic clamp. This effect was more pronounced in
subjects with impaired glucose tolerance.27 The same inves-
tigators showed changes in interleukin-6 (but not tumour
necrosis factor-a) plasma concentrations in type 2 diabetic
patients after a carbohydrate meal.28 Thus, blood glucose
excursions may induce a proinflammatory response.
Several in vitro studies demonstrated cytotoxic effects of
high glucose levels in various cell types.29–31 Of interest is the
demonstration by Risso and colleagues that intermittent high
glucose levels induced more apoptosis than constant corre-
sponding glucose levels in human umbilical vein endothelial
cells.30
Four main molecular mechanisms underlying the hyper-
glycaemia-induced vascular damage have recently been
reviewed,31 all of which are the result of intracellular
hyperglycaemia. These include increased polyol pathway
influx; increased advanced glycation end-product formation;
activation of protein kinase C isoforms; and increased hexo-
samine pathway flux. These seemingly different mechanisms
are the result of a single process—that is, overproduction of
superoxide by the mitochondrial electron transport chain.
This hyperglycaemia-induced oxidative stress ultimately
results in modification of intracellular proteins resulting in
an altered function, DNA damage, activation of the tran-
scription factor nuclear factor-kB, causing abnormal changes
in gene expression, decreased production of nitric oxide, and
increased expression of cytokines, growth factors and pro-
coagulant and proinflammatory molecules.31
Taken together, postload or postprandial glucose levels are
associated with enhanced risk of cardiovascular disease.
However, most epidemiological studies addressing the con-
tribution of postload glucose levels to cardiovascular disease
risk, especially the early ones, did not take into account the
earlier mentioned classical risk factors, such as dyslipidae-
mia. In studies investigating the relationship between post-
load glucose and cardiovascular disease risk, adjustment for
blood pressure, lipids and smoking, resulted in considerable
attenuation of this association.32 33 These data indicate that
postload glucose may not be an independent cardiovascular
disease risk factor but rather a risk marker, suggestive of
underlying other metabolic disturbances, such as insulin
resistance and dyslipidaemia, that may have an even greater
impact on cardiovascular disease risk.
In conclusion, evidence of postprandial hyperglycaemia as
an independent risk factor is not convincing. Therefore, the
observed association between postload glucose excursions
with cardiovascular disease is at least partly explained by the
presence of insulin resistance and related cardiovascular
disease risk factors.
POSTPRANDIAL HYPERTRIGLYCERAEMIA
In the western diet, more than 40% of the energy intake is
derived from fats. Figure 1 demonstrates a schematic repre-
sentation of the metabolic pathways of dietary fats leading to
triglyceride-rich lipoproteins (TRL) and endogenous TRL
production.34 In the insulin-resistant state the production of
very low density lipoprotein (VLDL) by the liver is inappro-
priately high. Together with a reduced lipoprotein lipase
activity this results in high triglyceride concentrations,
especially in the postprandial state. The large amount of
TRLs and their prolonged residence time in the circulation
may lead to increased exchange of the core lipid cholesteryl
ester for triglycerides between TRL and LDL and HDL
particles mediated by cholesteryl ester transfer protein. This
process enriches LDL and HDL with triglyceride, and these
particles are subsequently more readily hydrolysed by hepatic
lipase resulting in smaller, denser LDL particles and lower
concentrations of HDL. These abnormalities may explain the
characteristic diabetic dyslipidaemia, which is now recog-
nised to be very atherogenic.34
Already in 1959 an association between plasma concentra-
tions and incident coronary heart disease was reported.35
However, the known inverse association between triglycer-
ides and HDL cholesterol makes it difficult to show an
independent association between plasma triglyceride and
atherosclerotic vascular disease. A recently performed meta-
analysis including data of 57 000 subjects from 17 studies
demonstrated that fasting triglyceride concentrations were
an independent risk factor for cardiovascular disease, also
when adjusted for HDL cholesterol.36 A 1 mmol/l increase in
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plasma triglyceride was associated with a relative risk of 1.3
for men and 1.8 for women.
In general practice, serum lipid concentrations including
triglycerides are measured in the morning after an overnight
fast. However, the fasting value should be considered the
nadir of the 24 hour triglyceride profile and could therefore
be misleadingly low. In the past few years several clinical
studies have suggested that high postprandial TRL may be
related to coronary heart and/or carotid artery disease in non-
diabetic and diabetic subjects.37–39 The Physician Health study,
including 14 916 men aged 40–84 years, with a follow up of
seven years, showed that the non-fasting triglyceride con-
centrations strongly predicted incident myocardial infarc-
tions, with a relative risk of 1.40 (95% confidence interval
1.10 to 1.77) per 1.13 mmol/l increase.38 This study suggests
that random or postprandial triglyceride concentrations
are an important indicator of cardiovascular disease risk.
Although fasting triglycerides are the most important
determinant of postprandial triglycerides,40 it may be argued
that in insulin resistant subjects with a delayed postprandial
TRL clearance, non-fasting triglycerides should be used to
approximate overall triglyceride exposure.
In male patients after a myocardial infarction, Karpe and
co-workers found that the progression of coronary lesions
over five years was related to the postprandial plasma levels
of small chylomicron remnants (Sf 20–60 apolipoprotein
B48).41 Adjustment for the possible confounding effect of
HDL and dense LDL apolipoprotein B concentrations did not
substantially alter the strength of this association. In line
with these findings are coronary angiography data described
by Mero et al, which suggest that especially small chylomi-
cron remnants are implicated in the progression of coronary
artery disease.16
In healthy and type 2 diabetic subjects, endothelial dysfunc-
tion, measured by ultrasound as FMD, has been associated
with high triglyceride excursions.42 43 Correlations between
postprandial TRL, impaired FMD and oxidative stress
markers have been demonstrated, suggesting that free radical
production may be an underlying mechanism.42 43 Supporting
this hypothesis is the finding that in healthy subjects this
effect could be attenuated by the antioxidant vitamin C.43
In vitro studies demonstrated increased adhesion molecule
expression in endothelial cells after incubating with chylo-
microns and VLDL.44 45 Using rat arterial rings, Lundman et al
showed impairment of endothelium-dependent relaxation
following exposure to the triglyceride-containing fat emul-
sion Intralipid (Pharmacia-Upjohn, Uppsala, Sweden), how-
ever, exposure to VLDL did not affect vascular function.45
Postprandial coagulation activation by TRL was demon-
strated by several investigators, however the underlying
mechanism(s) are not fully understood.46 47 An elegant study
performed by Silveira et al suggests an important role for the
intrinsic coagulation pathway, based on in vivo activation of
factor XI by triglyceride.46 Other prothrombotic changes
occurring with an oral fat load are increased plasmin
activator inhibitor-1 (PAI-1) activity and PAI-1 antigen.48
Postprandial lipaemia enhanced platelet P-selectin expres-
sion without affecting other markers of platelet activation.49
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Figure 1 Lipid metabolism in vivo. Dietary fatty acids (FA) are absorbed from the gut and converted to triglycerides to be incorporated into
chylomicrons in the intestinal epithelial cells. The triglyceride-rich apolipoprotein (apo) B48 containing chylomicrons enter the plasma via the intestinal
lymph. Lipoprotein lipase (LPL) hydrolyses the triglyceride in chylomicrons to fatty acids, which are taken up by muscle cells for oxidation or adipocytes
for storage. The remaining particles, the chylomicron remnants, are removed from the circulation by the liver through binding of their surface apoE to
the low density lipoprotein (LDL) receptor or LDL receptor related protein. Very low density lipoprotein (VLDL) particles are triglyceride-rich apoB100
containing particles, synthesised by the liver. As with chylomicrons, VLDL triglycerides are hydrolysed by LPL. VLDL remnants or intermediate density
lipoproteins (IDL) are taken up by liver receptors via apoE or converted to LDL. Chylomicrons, VLDL and their respective remnants (RLP, remnant
lipoproteins) are termed triglyceride-rich lipoproteins (TRL). Under physiological conditions, insulin, which is raised in the postprandial state, suppresses
lipolysis from adipose tissue and hepatic VLDL production, however, this insulin action is inappropriate in insulin resistance and type 2 diabetes,
resulting in high TRL concentrations. The large amount of TRL and their prolonged residence time in the circulation increase the exchange of esterified
cholesterol from high density lipoprotein (HDL) and LDL to TRL and of triglycerides to LDL and HDL particles, which is mediated by cholesterol-ester
transfer protein (CETP). Triglyceride enrichment of LDL particles renders them better substrates for hepatic lipase (HL), which hydrolyses triglycerides
from the core of LDL and turns them into smaller and denser particles. Small dense LDL are more atherogenic as they readily enter the subendothelial
space and become oxidised. Triglyceride enriched HDL particles are smaller and are more rapidly catabolysed, which may explain the observed low
plasma HDL in insulin resistance and type 2 diabetes.34
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The effect of a high fat meal (50 g of fat) on cytokine
concentrations, reflecting the inflammatory state, was
studied in healthy and type 2 diabetic patients.28 In healthy
subjects, significant correlations were found between post-
prandial triglyceride and tumour necrosis factor-a levels,
whereas in diabetic patients also a positive correlation
between postprandial plasma triglyceride and interleukin-6
concentrations was observed. Antioxidant supplementation
lowered the rise of the cytokines, suggesting that the cytokine
response to triglycerides was mediated by oxidative stress.
To summarise, historically, in diabetic patients, most
emphasis was laid on hyperglycaemia, whereas recent
evidence demonstrates the importance of dyslipidaemia, in
particular hypertriglyceridaemia, as a cardiovascular disease
risk factor. Although at present, epidemiological and long
term intervention studies are largely lacking, in vivo data
convincingly show an association between postprandial TRL
and indicators of cardiovascular disease. Similar to post-
prandial hyperglycaemia, both in vivo and in vitro studies
indicate that (postprandial) increases in triglycerides are
proinflammatory, prothrombotic, and adversely affect several
endothelial functions, by inducing oxidative stress (fig 2).
Therefore, it is feasible that prolonged postprandial hyper-
triglyceridaemia leads to an atherogenic environment in vivo.
However, as for postprandial hyperglycaemia the evidence for
postprandial hypertriglyceridaemia as independent in cardi-
ovascular disease is still scanty. More evidence, which can
only be obtained from large prospective studies, is certainly
required.
THERAPEUTIC INTERVENTIONS
Drugs that have been effective in reducing meal related
glucose excursions are the a-glucosidase inhibitors, the short
acting insulin analogues, and the meglitinides.50–52
Recently, the STOP-NIDDM study showed a lower inci-
dence of hypertension and myocardial infarction after
treatment with the a-glucosidase inhibitor acarbose.53 These
findings should be interpreted with some caution as the
study was not designed to assess the effect of acarbose on
cardiovascular disease endpoints. The prospectively prede-
fined endpoint was conversion to diabetes, however, in the
final report 10 different cardiovascular disease endpoints
were mentioned, including angina and peripheral vascular
disease. In addition, it can not be excluded that the reduction
in cardiovascular disease endpoints is the result of lowering
triglycerides, since a triglyceride lowering effect of acarbose is
described.54
Metformin is the only blood glucose-lowering drug that
has been shown to lower diabetes related and cardiovascular
disease endpoints in obese type 2 diabetic patients. Based on
the proposed working mechanism,55 an effect on meal related
glucose excursions can not be expected, but metformin was
shown to reduce postprandial chylomicron concentrations.56
Correction of postprandial hyperglycaemia, for example
with insulin secretion enhancers, will not only affect glucose
levels but probably also the postprandial lipid responses.
However, recently Vakkilainen et al demonstrated that nateg-
linide and glibenclamide increased postprandial insulin
secretion and decreased postprandial glycaemia, but neither
drug attenuated postprandial lipaemia in type 2 diabetic
subjects with good glycaemic control.57
Intensive insulin treatment may improve diabetic dyslipi-
daemia to some extent, however, an entire correction of the
atherogenic lipid profile, including postprandial hypertrigly-
ceridaemia, may not be achieved.58
The lipid lowering drugs—that is, hydroxymethylglutaryl
coenzyme A reductase inhibitors (statins), and peroxi-
some proliferator-activated receptor a-agonists (fibrates),
are established as most efficient agents that reduce cardio-
vascular disease morbidity and mortality in various high risk
populations.59 60 Statins inhibit cholesterol synthesis and up-
regulate the hepatic LDL receptor, whereas fibrates increase
LPL activity and limit hepatic VLDL secretion. Based on their
respective working mechanisms, the most benefit on post-
prandial lipidaemia may be expected from fibrates. Indeed,
fibrate treatment reduced postprandial triglyceride levels by
30%–50%.61 The proposed beneficial effect of fibrates on
postprandial endothelial function measured by FMD, how-
ever, is disappointing.61 62 Statins tend to induce a modest
lowering of both fasting and postprandial triglycerides.61 63
However, statin treatment showed a marked beneficial effect
on postprandial induced oxidative stress and endothe-
lial function.63 Independently of their cholesterol-lowering
action, statins seem to have anti-inflammatory and vasculo-
protective effects (‘‘pleiotropic’’ effects).64
We conclude that the high cardiovascular disease morbid-
ity and mortality associated with type 2 diabetes is at least
partly due to a prolonged and exaggerated postprandial state
in these patients. To date, however, controlled randomised
intervention studies showing that postprandial both glucose
and triglyceride lowering results in amelioration of clinically
relevant endpoints are lacking.
These conclusions should in no way distract from the
therapeutic aim to achieve target glycated haemoglobin and
lipid values in patients with type 2 diabetes.
RECOMMENDATIONS FOR FUTURE RESEARCH AND
TESTING POSTLOAD DYSMETABOLISM
As discussed above, although the beneficial effect of therapy
targeting postprandial dysmetabolism still needs to be estab-
lished, studies assessing the true atherogenic exposure of the
vascular system in high risk patients should abandon the
classical glucose centred view and use physiological tests
combining glucose and lipid loads. Most studies mentioned
earlier demonstrated the effects of postprandial dysmetabo-
lism on a single and rather artificial challenge, like a liquid
75 g glucose or liquid fat load. In daily life, most meals
Central obesity, insulin resistance, type 2 diabetes
(Postprandial) dysmetabolism:
    Hyperglycaemia
Hyperlipidaemia 
Oxidative stress
Coagulation activation
Inflammation activation
Endothelial dysfunctions
Cardiovascular disease
Figure 2 Insulin resistant states and type 2 diabetes are characterised
by high circulating levels of atherogenic lipid particles due to an
increased supply of fatty acids to the liver and defective hepatic
clearance of lipoproteins. In the postprandial state, the lipid
abnormalities are further exaggerated, with an additional adverse effect
of meal induced hyperglycaemia. These postprandial metabolic
derangements increase the production of reactive oxygen species
causing oxidative stress and functional abnormalities of the vascular
endothelium at several levels, including impairment of vasoreactivity,
increased coagulation and inflammation activation, and increased
vascular permeability. Collectively, postprandial dysmetabolism and the
associated oxidative stress may link insulin resistance and type 2
diabetes to the disproportional incidence of cardiovascular disease in
these high risk populations.
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consumed are mixed and of solid consistence. Ceriello and
co-workers showed a cumulative adverse effect of postpran-
dial hypertriglyceridemia and hyperglycaemia on endothelial
function.63 The effect of a single component challenge possi-
bly underestimates the real life postprandial dysmetabolic
state and we therefore recommend the use of standardised
mixed meal containing of at least 75 g of carbohydrates and
50 g of fat in future postprandial (intervention) studies.
ACKNOWLEDGEMENTS
MET is supported by a grant from the Dutch Diabetes Foundation
(grant no 2000.00.025).
QUESTIONS (TRUE/FALSE; ANSWERS AT END OF
REFERENCES)
1. In the next 30 years, the highest incidence of type 2
diabetes may be expected in the developed countries.
2. Hyperglycaemia is the result of insulin resistance.
3. The so-called traditional risk factors cannot fully explain
the excessive cardiovascular disease risk in type 2 diabetic
patients.
4. Endothelial functions can be measured directly in
humans using ultrasound techniques.
5. Evidence suggests that high postload or postprandial
glucose levels constitute an independent risk factor for the
development of cardiovascular disease.
6. In the insulin resistant state, high VLDL concentrations
are the result of an increased flux of chylomicrons from the
gut due to a reduced lipoprotein lipase activity.
7. The fasting triglyceride value should be considered the
nadir of the 24 hour triglyceride profile and could therefore
be misleadingly low.
8. Statins have been shown to reduce postprandial
triglyceride levels more adequately than fibrates and have a
beneficial effect on postprandial induced oxidative stress.
9. The effect of a single nutrient component challenge
possibly underestimates the impact of real life postprandial
state.
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ANSWERS
1. False. The excessive global increase in the occurrence of
type 2 diabetes may be explained by the vast spreading of
western lifestyle patterns, including consumption of energy
dense foods and less physical activity, in parts of the world
with the highest population densities—that is, the developing
countries.
2. False. Hyperglycaemia is the result of progressive
pancreatic b-cell failure.
3. True. Absolute risk of death by cardiovascular disease
was much higher for diabetic than non-diabetic men of every
age stratum, ethnic background, and risk factor level—
overall three times higher, with adjustment for age, race,
income, serum cholesterol level, systolic blood pressure, and
smoking.5
4. False. Endothelial function can only be estimated—
indirectly—by provoking the endothelium to release nitric
oxide resulting in vasodilatation that can be imaged and
quantitated.
5. False. Postload glucose may not be an independent
cardiovascular disease risk factor but rather a risk marker,
suggestive of underlying metabolic disturbances that collec-
tively impact on cardiovascular disease risk.
6. False. In the insulin resistant state inappropriate
production of VLDL by the liver occurs, due to impaired
suppression of VLDL triglyceride by insulin (hepatic insulin
resistance) and an increased substrate (fatty acid) flux to the
liver.
7. True. In clinical practice triglycerides are measured in the
morning after an overnight fasting period. Triglyceride
profiles of type 2 diabetic patients show that after breakfast
their concentrations gradually increase after consecutive
meals and the peak concentration is achieved between dinner
and bedtime.
8. False. Based on their working mechanism, that is,
increasing (postprandial ) lipoprotein lipase activity, but also
in practice, fibrates, rather than statins reduce postprandial
triglycerides. Statins tend to induce a modest lowering of
fasting and postprandial triglyceride levels.
9. True. A cumulative effect of postprandial hypertriglycer-
idaemia and hyperglycaemia on endothelial function has
been demonstrated, possibly due to potentiation of oxidative
stress mechanisms.
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